Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $14.82, up 2.28% on the session, giving a market capitalisation of $557.5M. On trailing twelve-month figures it carries a trailing P/E of -8.57, a net margin of 0.0%. Its beta of 0.74 implies it has historically moved less than the broad market.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Contineum Therapeutics, Inc. is most often compared with the following Healthcare names: